Beyond Painkillers: How Modern Rheumatology Treatment Is Changing Lives

If you or someone you know has been diagnosed with inflammatory arthritis, you may have an outdated picture of what the condition means. Today, the treatment landscape has been transformed. With early diagnosis and modern therapies, most patients can achieve remission — meaning no pain, no swelling, and no ongoing joint damage.

Why Painkillers Are Not Enough

Many patients with early inflammatory arthritis are initially managed with painkillers and anti-inflammatory medications. While these provide symptom relief, they do nothing to stop the underlying disease process. The immune system continues to attack the joints, and damage accumulates silently. This is why rheumatologists distinguish between symptomatic treatment and disease-modifying treatment that targets the immune dysfunction causing inflammation.

Disease-Modifying Drugs: The Foundation

Disease-modifying antirheumatic drugs (DMARDs) are the cornerstone of treatment. Methotrexate has been the gold standard for over 30 years. Despite its name suggesting a connection to chemotherapy, the doses used in rheumatology are much lower with an excellent long-term safety record.

Methotrexate is typically taken once a week. It works by dampening the overactive immune response. Most patients notice improvement within 8 to 12 weeks. Other conventional DMARDs include sulfasalazine, leflunomide, and hydroxychloroquine.

Biologic Therapies: Targeted Treatment

For patients who do not respond to conventional DMARDs, biologic therapies target specific molecules driving inflammation. Anti-TNF agents such as adalimumab and etanercept can produce dramatic improvement. IL-6 inhibitors such as tocilizumab are effective for patients with high systemic inflammation. B-cell depleting therapies and T-cell co-stimulation blockers offer additional options.

Biologics are administered as self-injections at home or intravenous infusions in clinic. The choice depends on the drug, patient preference, and clinical circumstances.

JAK Inhibitors: The Newest Option

JAK inhibitors are the newest targeted therapy class. Unlike biologics, they are taken as tablets — a significant advantage. They work by blocking enzymes inside immune cells that drive inflammation. Currently available options include tofacitinib, baricitinib, upadacitinib, and filgotinib, with rapid onset often within two to four weeks.

As a Principal Investigator in clinical trials, I am closely involved in evaluating newer treatments and can discuss potential eligibility for trials offering access to cutting-edge therapies.

The Treat-to-Target Approach

Modern rheumatology follows a treat-to-target strategy — setting a clear goal of remission and systematically adjusting treatment until it is achieved. At each follow-up, I assess disease activity using validated measures and escalate treatment if the target has not been reached. This proactive approach produces significantly better outcomes.

What This Means for You

If you have been recently diagnosed, the outlook has never been better. If your current treatment is not controlling your symptoms, there may be options you have not tried. I would encourage specialist review if you have persistent joint swelling despite treatment or want to discuss newer options.

Private consultations at The Beaumont Hospital, Bolton. Self-referral accepted. Call 01204 404404. Most major insurers accepted.

*Last medically reviewed by Dr Leena Das, April 2026*